Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-557-2 | CAS number: 122-60-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- repeated dose toxicity: inhalation
- Remarks:
- other: Acute, subacute and sub chronic exposure studies were performed
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not reported
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Although this study was not conducted in accordance with current international guidelines or GLP, in accordance with REACH Annex XI, Section 1.1.2, the study was conducted under the same scientific principles of the repeated dose toxicity: inhalation test and adequate documentation of the study is provided. The study is therefore considered adequate for fulfilling this endpoint and for risk assessment purposes.
Data source
Reference
- Reference Type:
- publication
- Title:
- The inhalation toxicity of phenylglycidyl ether. I. 90-day inhalation study
- Author:
- James B Terrill
- Year:
- 1 977
- Bibliographic source:
- Terrill, J.B. and Lee, K.P. (1977) The inhalation toxicity of phenylglycidyl ether. I. 90-day inhalation study. Toxicology and Applied Pharmacology, 42:263-269.
Materials and methods
- Principles of method if other than guideline:
- This study was conducted in 1977, before OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study) was adopted in 1981. Although this study was not conducted in accordance with OECD 413, the methods and analyses used can be considered as being equivalent to OECD 413 as described herein.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- 2,3-epoxypropyl phenyl ether
- EC Number:
- 204-557-2
- EC Name:
- 2,3-epoxypropyl phenyl ether
- Cas Number:
- 122-60-1
- Molecular formula:
- C9H10O2
- IUPAC Name:
- 2-(phenoxymethyl)oxirane
- Details on test material:
- PGE purity was 99.6 % with trace amounts of phenol and diglycidyl ether as determined by gas chromatography.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Sprague-Dawley (ChR-CD, Charles River Breeding Labs) rats were given 1 week of acclimatisation prior to testing. At the start of the test, body weights were 250-260 g for males and 180-200 g for females. Food and water were given ad libitum, except during exposure.
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- The test atmosphere was generated by syringe-driving unheated liquid into a tube furnace. The furnace tube (2 in. i.d. x 24 in. length, stainless steel) was constructed in such a way that the wall temperature of the delivery tube and the pure nitrogen stream (10 L/min) were the same temperature, 310 degrees celsius. The nitrogen-PGE atmosphere was delivered directly to the exposure chamber.
2-week inhalation studies were carried out in a 20 litre glass chamber. Chamber temperature was maintained below 32 degrees celsius by cooling with ice packs and by dilution of concentrated PGE vapours with a room temperature oxygen/air mixture.
Subchronic exposures were run in 5 cubic metre chambers. Satisfactory chamber temperature (< 32 degrees celsius) and oxygen levels were maintained by the 2000 L/min inlet air velocity. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Chamber atmospheres were monitored for PGE and phenol by UV analysis of impinger samples. Typically a 1 L/min sample was drawn through 15 ml of 0.1 N NaOH in 50:50 ethanol:water for 10 minutes. At 5 ppm (v/v), this solution has an absorbance of 0.4 (1 cm cell) at lambda max of 270nm. Phenol has a lambda max at 288 nm and can be detected at 5 % or greater of the PGE concentration (minimum sensitivity: 1 ppm of PGE, phenol >/= 0.05 ppm; 5 ppm, phenol >/= 0.25 ppm; 12 ppm, phenol >/= 0.6 ppm) using the analytical procedure.
Samples were taken hourly and the final concentrations were calculated on a time-weighted-average (TWA) basis (+/- σ).
Phenol, the major degradation product of heated PGE, was not detected at the limit of analytical sensitivity (5 % of the PGE concentration). - Duration of treatment / exposure:
- 2 week study: 4 hours per day
90 day study: 6 hours per day - Frequency of treatment:
- 2 week study: 5 days per week (10 exposures)
90 day study: 5 days per week (63 exposures)
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
29 ppm (v/v) - 2 week study
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
1.3 ± 0.5 ppm (v/v) - 90 day study
Basis:
analytical conc.
- Remarks:
- Doses / Concentrations:
5.0 ± 1.3 ppm (v/v) - 90 day study
Basis:
analytical conc.
- Remarks:
- Doses / Concentrations:
11.8 ± 2.8 ppm - 90 day study
Basis:
analytical conc.
- No. of animals per sex per dose:
- 2-week study: 6 male rats per dose level.
90 day study: 32 rats per sex per dose level. - Control animals:
- yes
- Details on study design:
- The highest dose level in the 90-day study was chosen on the basis of: first, a calculated saturated vapour concentration of 13 ppm, using the value of 0.01 mm Hg at 25 degrees celsius; and second, treatment-related effects in the preceding 2-week study at 29 ppm.
Examinations
- Observations and examinations performed and frequency:
- 2 week study:
All rats were weighed and physically examined daily.
90 day study:
Physical inspection of all animals was conducted daily and body weights were measured twice a week. On days 30, 60 and 90 of exposure and at 30, 60, and 90 days post exposure, blood and urine samples (from 10 rats per sex per dose level) were taken for examination and analyses.
Hematologic and clinical chemical indices were determined from blood collections by the following procedures: serum glutamic pyruvic transaminase (SGPT), bilirubin, alkaline phosphatase, glucose and RBC, WBC, PCV, and Hb - conventional methods.
Urine collections from rats were analysed by lab-Stir and other conventional methods for osmolality, volume, colour, appearance of sediment, sugar, protein, blood, and urobilinogen. - Sacrifice and pathology:
- 2 week study:
At the end of the test half of the rats from each group were sacrificed for histopathologic evaluation. After a 2 week postexposure period, the remaining rats were sacrificed and examined histopathologically.
90 day study:
Rats were sacrificed at 30, 60 and 90 days of exposure and at 28-days postexposure for histopathologic evaluation.
All major tissues and organs were examined both grossly and microscopically. The brain, heart, lungs, liver, kidneys, spleen, pituitary gland, thyroid, adrenals, and testes (ovaries for females) were weighed, and the ratio of organ to body weight was calculated. The lung and trachea were inflated with 10 % formalin. Sections of heart*, aorta, spleen*, bone marrow, lymph node, lung*, thorax*, liver*, stomach*, duodenum, jejunum, ilium, cecum, colon, rectum, pancreas*, kidney*, urinary bladder, salivary gland, thyroid*, adrenal gland*, pituitary gland*, thymus*, testis*, epididymis, prostate (or ovary, uterus, mammary gland) brain*, spinal chord, eye, sciatic nerve, muscle* and skin* were fixed in Bouin's solution and stained with hematoxylin eosin for subsequent microscopic examination.
* - These sections were also examined in the 2 week study. - Statistics:
- Results of blood and urine examinations were analysed by split-unit analysis of variance and least significant difference test. Significance was assessed at the 0.05 probability level.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Alopecia
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Alopecia
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- 2 week study:
Depression in weight gain, atrophic changes in the kidney, liver, spleen, thymus and testes, depletion of hepatic glycogen, and chronic catarrhal tracheitis were observed.
90 day study:
Weight gains for treated and control rats were similar, all rats appeared to be unaffected by treatment during and after exposure, except for significant hair loss which occurred in both sexes at the 5 and 12 ppm treatment levels after about 45 days of exposure. At the end of the 90-day exposure period, 10 % of the males and 25 % of the females at the two highest dose levels exhibited areas of alopecia. The alopecia appeared bilateral and frequently developed on the dorsal anterior portion of the body, especially the head, neck, and shoulder region. Occasionally, hair loss was found posterior to the abdominal area and on the hind legs. The alopecia was frequently symmetrically distributed and sharply demarcated from the adjacent normal hair coat. On the other hand, weight gain and qualitative indices such as behaviour and sociability for all treated rats was not altered as compared to the control group. Whether or not the hair loss was reversible could not be assessed, for all the affected rats were sacrificed after the 90th exposure for histopathological examination.
Results of blood and urine examinations showed an occasional significant difference (p < 0.05) between treated and control animals. However, review of all test data indicated these variations were random and not due to treatment.
Histopathologically, all tissues and organs from all test animals showed no significant changes when compared to controls at any sacrifice interval, except for the skin/hair system of those rats in the 5 and 12 ppm treated groups which exhibited alopecia. In the bald areas, some hair follicles were damaged, while others were in growing phases. Also, these areas showed very slight acanthosis, parakeratosis, and inflammatory cellular infiltration of the dermis and hair follicles. The hair shaft was disintegrated due to cellular infiltration and necrosis of the hair follicles. Frequently, the upper portions of the hair shaft were destroyed or embedded in excessive keratin material forming epidermal pearls. Normal hair growth appeared disturbed by destruction of the hair follicles, inflammatory cell infiltration, and hyperkeratosis.
Effect levels
- Dose descriptor:
- NOAEC
- Effect level:
- >= 11.8 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: The only effects observed in this study were local effects: respiratory irritation (29 ppm in 2 week exposure study) and patchy, bilateral hair loss, possibly as a result of dermal irritation (5 and 12 ppm in 90 day study).
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The estimated inhalatory NOAEC for rats exposed to vapours of PGE is 11.8 ppm.
However, local effects (respiratory irritation and alopecia) were observed at 1.3 and 5 ppm; these observations should also be considered in the derivation of DNELs for skin and respiratory irritation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.